| If this is not your name, click here. | | |
| | Contact Us | Order Now | Journals | Bookstore | Register a colleague | | |
| | | ![]() Celebra Receives Priority FDA Review ST. LOUIS, MO -- Aug. 25, 1998 -- Monsanto's G.D. Searle & Co.’s Celebra(TM) (celecoxib) has received priority review designation from the United States Food and Drug Administration. Celebra's submitted indication is for acute or chronic use in the treatment of the signs and symptoms of osteoarthritis and rheumatoid arthritis and for the management of pain. The compound is being submitted as a proposed member of a new class of agents known as specific COX-2 inhibitors. Searle and Pfizer Inc. will develop and commercialise Celebra in all areas except Japan. Related Links: Searle & Co., Pfizer Inc.
|